<DOC>
	<DOCNO>NCT00320775</DOCNO>
	<brief_summary>The purpose trial ass ocular systemic safety tolerability single intravitreal injection VEGF Trap patient subfoveal choroidal neovascularization ( CNV ) due AMD .</brief_summary>
	<brief_title>Safety Tolerability Study Intravitreal VEGF-Trap Administration Patients With Neovascular AMD</brief_title>
	<detailed_description>This study consist three part , Part A , Part B Part C. Part A dose escalation . Part B terminate early . The ( one ) subject receive Macugen discuss website . Part C subject receive one two dos VEGF Trap ( 0.15 mg 4.0 mg ) . This first study human subject receive intravitreal injection VEGF Trap study eye .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Subfoveal CNV secondary AMD . Central retinal/lesion thickness ≥ 250µm measured optical coherence tomography ( OCT ) . ETDRS bestcorrected visual acuity : 20/40 ( 73 letter ) bad Clear ocular medium clear lens ( e ) permit good quality stereoscopic fundus photography . Prior treatment VEGF Trap , bevacizumab ranibizumab . Any investigational agent within 12 week Visit 2 ( Day 1 ) . Presence cause CNV . Active ocular infection .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
</DOC>